8-K · PFE
Pfizer files an 8-K on director or officer changes
Pfizer filed a Form 8-K on Nov 3, 2026 at 4:19 PM ET under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers).
Under Item 5.02, the filing says: “On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”).”
The filing attaches material as Exhibit 99.1.
Source
- 8-K filed Nov 3, 2026 (document)
- Filing index on SEC EDGAR (all documents and exhibits)
Pfizer company file → · More Pfizer filings
Disclosures
- Editor holdings in PFE
- The editor holds no position in Pfizer (PFE). As of Nov 11, 2026.
- Last updated
- Nov 3, 2026
A summary of a public filing for general education, the same for every reader. Not a recommendation to buy, sell or hold PFE.